Hostname: page-component-8448b6f56d-c47g7 Total loading time: 0 Render date: 2024-04-24T13:38:22.854Z Has data issue: false hasContentIssue false
  • English
  • Français

Surveillance of adverse drug events associated with tocilizumab in hospitalized veterans with coronavirus disease 2019 (COVID-19) to inform patient safety and pandemic preparedness

Part of: SARS-CoV-2/COVID-19

Published online by Cambridge University Press:  14 May 2021

Rupak Datta Open the ORCID record for Rupak Datta [Opens in a new window] ,
Alexis Barrett ,
Muriel Burk ,
Cedric Salone ,
Anthony Au ,
Francesca Cunningham ,
Ann Fisher ,
Louise Marie Dembry  and
Kathleen M. Akgün
Rupak Datta*
Affiliation:
Hospital Epidemiology and Infection Prevention Program, Veterans Affairs (VA) Connecticut Healthcare System, West Haven, Connecticut Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut
Alexis Barrett
Affiliation:
VA Pharmacy Benefits Management Services and Center for Medication Safety, Hines VA, Hines, Illinois
Muriel Burk
Affiliation:
VA Pharmacy Benefits Management Services and Center for Medication Safety, Hines VA, Hines, Illinois
Cedric Salone
Affiliation:
VA Pharmacy Benefits Management Services and Center for Medication Safety, Hines VA, Hines, Illinois
Anthony Au
Affiliation:
VA Pharmacy Benefits Management Services and Center for Medication Safety, Hines VA, Hines, Illinois
Francesca Cunningham
Affiliation:
VA Pharmacy Benefits Management Services and Center for Medication Safety, Hines VA, Hines, Illinois
Ann Fisher
Affiliation:
Hospital Epidemiology and Infection Prevention Program, Veterans Affairs (VA) Connecticut Healthcare System, West Haven, Connecticut Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut
Louise Marie Dembry
Affiliation:
Hospital Epidemiology and Infection Prevention Program, Veterans Affairs (VA) Connecticut Healthcare System, West Haven, Connecticut Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut
Kathleen M. Akgün
Affiliation:
Pain Research, Informatics, Multimorbidities, and Education Center, VA Connecticut Healthcare System, West Haven, Connecticut Department of Medicine, VA Connecticut Healthcare System, West Haven, Connecticut Section of Pulmonary, Critical Care, and Sleep Medicine, Yale School of Medicine, New Haven, Connecticut
*
Author for correspondence: Rupak Datta, E-mail: rupak.datta@yale.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

We evaluated adverse drug events (ADEs) by chart review in a random national sample of 428 veterans with coronavirus disease 2019 (COVID-19) who received tocilizumab (n = 173 of 428). ADEs (median time, 5 days) occurred in 51 of 173 (29%) and included hepatoxicity (n = 29) and infection (n = 13). Concomitant medication discontinuation occurred in 22% of ADE patients; mortality was 39%.

Type
Concise Communication
Information
Infection Control & Hospital Epidemiology , Volume 43 , Issue 10 , October 2022 , pp. 1488 - 1491
Check for updates
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Guaraldi, G, Meschiari, M, Cozzi-Lepri, A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2020;2:e474–e484.CrossRefGoogle ScholarPubMed
Somers, EC, Eschenauer, GA, Troost, JP, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis 2020. doi: 10.1093/cid/ciaa954.CrossRefGoogle Scholar
Lan, S-H, Lai, C-C, Huang, H-T, Chang, S-P, Lu, L-C and Hsueh, P-R. Tocilizumab for severe COVID-19: a systematic review and meta-analysis. Int J Antimicrob Agents 2020;56:106103.Google ScholarPubMed
Actemra (tocilizumab) prescribing information. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125276s114lbl.pdf. Accessed October 20, 2020.Google Scholar
Mazdeyasna, H, Nori, P, Patel, P. et al. Antimicrobial stewardship at the core of COVID-19 response efforts: implications for sustaining and building programs. Curr Infect Dis Rep 2020;22(9):23.CrossRefGoogle ScholarPubMed
Food and Drug Administration. Sentinel Initiative website. https://www.sentinelinitiative.org/. Accessed October 21, 2020.Google Scholar
Rogers, WH, Kazis, LE, Miller, DR, et al. Comparing the health status of VA and non-VA ambulatory patients: the veterans’ health and medical outcomes studies. J Ambul Care Manage 2004;27:249–262.CrossRefGoogle ScholarPubMed
Rentsch, CT, Kidwai-Khan, F, Tate, JP, et al. Patterns of COVID-19 testing and mortality by race and ethnicity among US veterans: a nationwide cohort study. PLoS Med 2020;17:e1003379.CrossRefGoogle ScholarPubMed
Hermine, O, Mariette, X, Tharaux, P, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med 2020. doi: 10.1001/jamainternmed.2020.6820.CrossRefGoogle Scholar
Salvarani, C, Dolci, G, Massari, M, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med 2020. doi: 10.1001/jamainternmed.2020.6615.Google Scholar
Supplementary material: File

Datta et al. supplementary material

Datta et al. supplementary material

Download Datta et al. supplementary material(File)
File 14.2 KB